BAZ2-ICR

CAS No. 1665195-94-7

BAZ2-ICR ( BAZ2 ICR )

Catalog No. M12539 CAS No. 1665195-94-7

BAZ2-ICR is a potent, selective and cell-active inhibitor of BAZ2A and BAZ2B bromodomains.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BAZ2-ICR
  • Note
    Research use only, not for human use.
  • Brief Description
    BAZ2-ICR is a potent, selective and cell-active inhibitor of BAZ2A and BAZ2B bromodomains.
  • Description
    BAZ2-ICR is a potent, selective and cell-active inhibitor of BAZ2A (Kd=109 nM; IC50=130 nM) and BAZ2B (Kd=170 nM; IC50=180 nM) bromodomains; demonstrates 15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.
  • Synonyms
    BAZ2 ICR
  • Pathway
    Chromatin/Epigenetic
  • Target
    Bromodomain
  • Recptor
    Bromodomain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1665195-94-7
  • Formula Weight
    357.42
  • Molecular Formula
    C20H19N7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN(N=C1)C=C1C2=C(C3=CC=C(C#N)C=C3)N(CCC4=CN(C)N=C4)C=N2
  • Chemical Name
    4-[4-(1-methyl-1H-pyrazol-4-yl)-1-[2-(1-methyl-1H-pyrazol-4-yl)ethyl]-1H-imidazol-5-yl]-benzonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Drouin L, et al. J Med Chem. 2015 Mar 12;58(5):2553-9.
molnova catalog
related products
  • ZL0454

    ZL0454 is a potent, highly selective small-molecule BRD4 inhibitor with IC50 of 49 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively.

  • BRD9-IN-28

    BRD9-IN-28 is a highly potent and selective BRD7/9 bromodomain inhibitor with pIC50 of 6.9, Kd of 68 nM for BRD9.

  • ZL0420

    ZL0420 is a potent, highly selective BRD4 inhibitor with IC50 of 27 and 32 nM for BRD4-BD1 and BRD4-BD2, respectively.